Republic of the Philippines
Cebu Normal University
Osmeña Blvd., Cebu City, 6000, Philippines
College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph
DRUG STUDY
Patient’s Initials: J.C.R Date of Admission: September 1, 2023 Diagnosis: Cerebrovascular Disease, Left MCA Territory, Atherothrombosis
Age: 69 y.o. Height: 155 cm Weight.: 62 kgs Clinical Intervention: N/I
Sex: Female Ward: North District Bed No.: 201-A Name of Physician: ______________
Drug Information Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities
Generic Name: Pharmacologic Pharmacodynamics or General Hypersensitivity to (per system preferably) Before Drug Administration:
Clopidogrel Bisulfate Classification: Mechanism of Action: Indication/s: clopidogrel; intracranial
Consequently, hemorrhage, peptic
Body as a Whole: Flu-like • Conduct a comprehensive patient
Blood formers, Inhibits platelet syndrome, fatigue, pain, assessment, including reviewing the patient's
clopidrogrel ulcer, or any other active
Coagulators aggregation by arthralgia, back pain. medical history, allergies, and current
Trade Name: Plavix prolongs bleeding pathologic bleeding;
selectively preventing the medications. Pay particular attention to any
time. pregnancy (category B). CV: Chest pain, edema,
binding of adenosine contraindications or potential drug
Discontinue clopidogrel hypertension,
Therapeutic diphosphate to its platelet Patient’s interactions that may affect the patient's
Minimum Dose: 75 7 d before surgery and thrombocytic purpura.
Classification: receptor. It is an analog Indication: safety or the effectiveness of clopidogrel.
mg during lactation. Safety
Anticoagulant, of ticlopidine. The drug's Secondary and efficacy not GI: Abdominal pain, • Educate the patient about clopidogrel's
Antiplatelet Agent effect on the adenosine prevention of MI, dyspepsia, diarrhea, purpose, which is to prevent blood clots and
established in children.
diphosphate receptor of a stroke, and nausea, reduce the risk of cardiovascular events.
Maximum Dose: 75 platelet is irreversible. vascular death in hypercholesterolemia. Explain its benefits, potential side effects,
mg patients with and the importance of adhering to the
Pharmacokinetics: recent MI, stroke, Hematologic: Thrombotic prescribed regimen.
unstable angina or thrombocytopenic
Absorption: Rapidly • Confirm the physician's order for clopidogrel,
Patient’s Dose: 75 established purpura, epistaxis.
absorbed from GI tract. ensuring the correct drug, dose, route, and
mg 1 tab OD peripheral arterial CNS: Headache, time. Check the medication label for
Onset: 2 h; reaches disease. dizziness, depression. accuracy and verify that it is within its
steady state in 3–7 d. expiration date.
Certification Date: 1 February 2021
Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page PAGE
check and type the registration number)
\* Arabic \*
MERGEFOR
Registration No. 52Q18778
MAT 1 of
Republic of the Philippines
Cebu Normal University
Osmeña Blvd., Cebu City, 6000, Philippines
College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph
Drug Information Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities
Route: PO Distribution: 94–98% Respiratory: URI, • Prepare the medication in the appropriate
protein bound. dyspnea, rhinitis, form (usually tablets) and ensure you have
bronchitis, cough. any necessary tools, such as water, to assist
Metabolism: Rapidly
Frequency: OD the patient in swallowing the tablet if needed.
hydrolyzed in plasma to Skin: Rash, pruritus.
• Advise patient to not breast feed while taking
active metabolite.
this drug.
Availability/Form: 75 Elimination: 50%
During Drug Administration:
mg tablets excreted in urine and
50% in feces. • Verify the patient's identity using at least two
Half-Life: 8 h. unique identifiers.
Contents: • Administer clopidogrel as prescribed,
Clopidogrel bisulfate typically orally. Ensure the patient can
comfortably swallow the tablet and provide
water if necessary.
• Continuously monitor the patient during and
immediately after drug administration. Look
for any immediate adverse reactions or signs
of an allergic reaction, such as rash, itching,
swelling, or difficulty breathing. If adverse
reactions occur, take appropriate action and
notify the healthcare provider.
• Accurately document the medication
administration details, including the date,
Certification Date: 1 February 2021
Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page PAGE
check and type the registration number)
\* Arabic \*
MERGEFOR
Registration No. 52Q18778
MAT 1 of
Republic of the Philippines
Cebu Normal University
Osmeña Blvd., Cebu City, 6000, Philippines
College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph
Drug Information Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities
time, dose, route, and any specific
instructions or observations.
After Drug Administration:
• Inform patient to report promptly any unusual
bleeding (e.g., black, tarry stools).
• Advise patient to avoid chronic aspirin or
NSAID use unless approved by physician.
• Monitor the patient's clinical condition and
any relevant laboratory tests (e.g., platelet
count) as ordered by the physician to assess
the effectiveness of clopidogrel therapy.
Report significant changes to the healthcare
provider for possible dose adjustments or
additional interventions.
• Maintain accurate records of the patient's
response to clopidogrel, any side effects or
changes in condition, and any subsequent
doses administered.
References (at least 2):
MIMS. (2023). Frusemide. Retrieved September 11, 2023 from https://www.mims.com/philippines/drug/info/clopidogrel?mtype=generic
RobHolland. (2023). Clopidogrel. Retrieved September 11, 2023 from http://www.robholland.com/Nursing/Drug_Guide/data/monographframes/C101.html
Certification Date: 1 February 2021
Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page PAGE
check and type the registration number)
\* Arabic \*
MERGEFOR
Registration No. 52Q18778
MAT 1 of
Republic of the Philippines
Cebu Normal University
Osmeña Blvd., Cebu City, 6000, Philippines
College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph
PRODUCT ASSESSMENT RUBRICS FOR DRUG STUDY
Student Name: Bridgette Jance T. Agura Year/Section: 3-B Date: September 11, 2023 Score: ___/30
Directions: Please select the appropriate rating using the following descriptions.
Element Very Satisfactory Satisfactory Needs Improvement Comments
Drug ☐ Accurately presented all of the patient and drug information ☐ Accurately presented most of the patient and drug ☐ Accurately presented some of the patient and drug information
Information (name [brand & generic], dosage [patient’s dose; min. & max], information related to the case. 1 missing information or error related to the case. 2 or more missing information or errors noted.
(10%) frequency, route, availability, contents) related to the case. [3] noted. [2] [1]
Classification ☐ Accurately presented the classification (therapeutic and ☐ Accurately presented the classification related to the drug ☐ Inaccurately presented the classification related to the drug.
(10%) pharmacologic) related to the drug. [3] but with 1 irrelevant information or error noted. [2] Classification is not relevant to the drug. [1]
☐ Accurately presented the indication/s (general & patient- ☐ Accurately presented the indication/s related to the drug but ☐ Inaccurately presented the indication/s related to the drug.
Indication (10%)
specific) related to the drug. [3] with 1 irrelevant information or error noted. [2] Indication is not relevant to the drug. [1]
Mechanism of ☐ Accurately presented the mechanism of action ☐ Accurately presented the mechanism of action of the drug ☐ Inaccurately presented the mechanism of action of the drug.
Action (10%) (pharmacokinetics, pharmacodynamics) of the drug. [3] but with 1 irrelevant information or error noted. [2] Mechanism of action is not relevant to the drug. [1]
☐ Accurately presented all of the common contraindications ☐ Accurately presented most of the common contraindications ☐ Accurately presented some of the common contraindications
Contraindication
related to the drug. [3] related to the drug. 1 missing information or error noted. [2] related to the drug. 2 or more missing information or errors noted.
(10%)
[1]
Side Effects ☐ Accurately presented all of the common side effects related to ☐ Accurately presented most of the common side effects ☐ Accurately presented some of the common side effects related
(10%) the drug. [3] related to the drug. 1-2 missing information or errors noted. [2] to the drug. 3 or more missing information or errors noted. [1]
Nursing ☐ Accurately presented all of the common nursing ☐ Accurately presented most of the common nursing ☐ Accurately presented some of the common nursing
Responsibilities responsibilities (before, during, and after) related to the drug. [9] responsibilities related to the drug. 1-2 missing information or responsibilities related to the drug. 3 or more missing information
(30%) errors noted. [7] or errors noted. [3]
Certification Date: 1 February 2021
Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page PAGE
check and type the registration number)
\* Arabic \*
MERGEFOR
Registration No. 52Q18778
MAT 1 of
Republic of the Philippines
Cebu Normal University
Osmeña Blvd., Cebu City, 6000, Philippines
College of Nursing
Telephone No.: (+63 32) 254 4837
Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph
☐ Presented at least 2 sources that are updated (within 5 years), ☐ Presented only one source that is updated (within 5 years), ☐ No source was presented. Sources are not updated (more than 5
References
relevant, and credible. [3] relevant, and credible. Other sources are not updated, credible years), relevant, and credible. [1]
(10%)
or relevant. [2]
Sub-score = ____ = ____ = ____
Evaluated by:
_______________________________________
Signature over Printed Name of Clinical Instructor
Certification Date: 1 February 2021
Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page PAGE
check and type the registration number)
\* Arabic \*
MERGEFOR
Registration No. 52Q18778
MAT 1 of
